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Summary The in vivo and in vitro effects of human a-interferon (IFN) on blood natural killer (NK) cell
activity were studied in patients with malignant melanoma. The initial response to an i.m. injection of IFN
was a depression of blood NK cell activity, being detectable at 4h and reaching a nadir at 12h. Blood NK
cell activity returned to or exceeded pretreatment levels within 24 h. The frequency of large granular
lymphocytes among peripheral blood lymphocytes (PBL), however, remained unchanged during the first 24h
of IFN treatment. In a single cell cytotoxicity assay in agarose the number of lymphocytes forming conjugates
with K562 target cells was not affected at 12-h points of IFN treatment, while the frequency of lytic
conjugates with dead target cells was decreased by 12 h. Thus, the number of active NK cells was reduced by
IFN administration. While in vitro exposure to IFN resulted in an augmentation of NK cell activity of PBL
from untreated patients, IFN failed to enhance the activity of PBL obtained 12h post IFN injection. When
PBL obtained 12h after IFN injection were cultured overnight, they recovered their responsiveness to NK-
boosting effects of IFN. Blood monocytes obtained at 12-h points from IFN-treated patients suppressed IFN-
induced enhancement of NK cell activity, although these monocytes did not inhibit the base line level of NK
cell activity. In contrast, the streptococcal preparation OK432 was able to augment NK cell activity of PBL
obtained 12h post IFN administration and of control PBL even in the presence of suppressor monocytes.
PBL obtained 24h post IFN injection expressing enhanced NK cell activity were also unresponsive to IFN in
vitro. However, monocytes obtained 24h after IFN injection were no longer able to inhibit IFN-induced
augmentation of NK cell activity. These results indicate that in vivo administration of IFN-a to cancer
patients results in rapid and transient generation of suppressor monocytes capable of inhibiting IFN-
dependent development of functional NK cell activity, which could be responsible for the initial and transient
decline in blood NK cell activity.
There is increasing evidence that natural killer
(NK) cells play an important role in host defence
mechanisms against tumours, microbes, and virus-
infected cells (Herberman, 1980, 1982), although the
actual biological significance of NK cells is not yet
understood. We have recently demonstrated that a
minor proportion of blood and tumour-associated
NK cells kill autologous tumour cells freshly
isolated from the same cancer patients (Uchida &
Micksche, 1983a). Recent reports have indicated
that human NK cells activity is strongly associated
with a morphological subpopulation of lymphoid
cells, termed large granular lymphocytes (LGL)
(Timonen et al., 1981). Although LGL are not
synonymous with NK cells, more than 50% of
LGL have been shown to function as active NK
cells by using a single cell level assay (Timonen et
al., 1982). The activity of NK cells appears to be
highly regulated in both positive and negative ways
(Herberman, 1980, 1982): Interferon (IFN) plays a
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central role in the augmentation of NK cell activity
(Gidlund et al., 1978; Trinchieri et al., 1978;
Herberman et al., 1979), whereas suppressor cells
inhibit NK cell activity (Uchida & Micksche,
1981a, 1983b; Uchida et al., 1982, 1984; Boldignon
et al., 1982). IFN has been demonstrated to
enhance NK cell activity through recruitment of
pre-NK cells that have pre-existing ability to bind
NK-susceptible target cells but cannot kill these
target cells and through activation of both pre-NK
cells and active NK cells (Saksela et al., 1979;
Targan & Dorey, 1980). We have previously
reported that the streptococcal preparation OK432
augments NK cell activity by activating LGL with
pre-existing capacity to recognize cells
independently of IFN induction (Uchida &
Micksche, 1981b, 1983b). On the other hand,
adherent types of suppressor cells from malignant
pleural effusions of cancer patients and from the
peripheral blood of postoperative cancer patients
have been reported to suppress the maintenance of
functional NK cells and the development of active
NK cells through IFN (Uchida & Micksche, 1981a,
1983b; Uchida et al., 1982, 1984).
Considerable attention has recently been paid to
the use of IFN as a new therapeutic approach for484 A. UCHIDA et al.
human cancer (Gutterman et al., 1980; Priestman,
1980). Since IFN is known to be an important
modulator of NK cell activity (Gidlund et al.,
1978; Trinchieri et al., 1978; Herberman et al.,
1979), several studies have focused on the changes
in blood NK cell activity of cancer patients
undergoing IFN treatment. Systemic administration
of IFN has been demonstrated to result in an
increase in blood NK cell activity (Huddlestone et
al., 1979; Einhorn et al., 1980, 1983; Golub et al.,
1982a, 1982b; Lotzova et al., 1982, 1983). An initial
decline in blood NK cell activity has also been
documented in patients with chronic hepatitis (Pape
et al., 1981), in cancer patients (Koren et al., 1983;
Golub et al., 1982a, 1982b), and in normal donors
(Karimiemi et al., 1980) 2 to 12 h after i.v. or i.m.
injections of IFN. The mechanism responsible for
the initial depression of blood NK cell activity
observed in patients receiving IFN, however, is
unclear. The present study was designed to
investigate the mechanism involved in the initial
decline in blood NK cell activity and
unresponsiveness of blood lymphocytes to NK-
boosting effects of IFN in cancer patients after IFN
administration.
Materials and methods
Patients and treatment
Twelve patients with malignant melanoma of Stage
I or II were entered into the study. The patients
had no history of previous anticancer chemotherapy
or radiation therapy at the time of the study. The
patients received an i.m. injection of a single dose
of 2 x 106 international units of human
lymphoblastoid IFN-a (Heriff Medical Aps, Omme,
Denmark). The purity of the IFN preparation was
106 IU of human IFN-amg-' protein. Normal
healthy donors were used as roughly age- and sex-
matched controls.
Cellpreparation
Lymphocyte-rich mononuclear cells were isolated
from heparinized peripheral blood by centrifugation
on Ficoll-Hypaque gradients and further
fractionated as described previously (Uchida &
Micksche, 1981a, 1981b, 1983a, 1983b, 1983c).
Mononuclear cells collected from the interface were
washed and suspended in RPMI 1640 medium
supplemented with 2mM L-glutamine, 25 mM
HEPES, 100 U penicillin ml-', 100 ug
streptomycin ml- ', and 10% heat-inactivated foetal
calf serum (FCS) (Gibco Bio-Cult, Glasgow,
Scotland) (complete medium). The mononuclear
cells were then incubated for 1 h at 37°C in plastic
dishes that had been precoated with FCS. After
incubation, nonadherent cells were removed, and
the dish was washed with cold medium. Adherent
cells were harvested from the dish after 15 min
incubation with Versene (1/5000, Gibco Bio-Cult)
and by vigorous washing with a pipette, then
washed and suspended in complete medium. The
adherent cells contained >94% monocytes as
judged by morphologic examination and nonspecific
esterase staining. The nonadherent cells were further
incubated on nylon-wool columns for 1 h at 37°C,
and then eluted with warm medium. The nylon-
wool nonadherent cells contained >98%
lymphocytes as judged by morphologic examination
of Giemsa-stained smears. Every fraction was
>97% viable by dye exclusion. Effector cells were
used either immediately or stored at 4°C at a
concentration of 106 ml-' in complete medium,
since under the condition there were no differences
in cytotoxicity of fresh and cultured cells (Uchida &
Micksche, 1981a).
51Cr release cytotoxicity assay
A 4h 51Cr release assay was performed using the
K562 human erythromyeloid leukemia cell line
(Lozzio & Lozzio, 1975) as targets, as detailed
elsewhere (Uchida & Micksche, 1981a, 1981b,
1983a, 1983b, 1983c). Briefly, 100,l 51Cr-labelled
target cells (5 x 103) and 100l 1 effector cells in
different numbers were added to each well of
round-bottomed microtiter plates. After 4h
incubation, the supernatant was collected, and the
specific 5 Cr release in percentage cytotoxicity was
calculated by the formula for triplicate samples: %
Cytotoxicity=(test cpm-spontaneous cpm)/(maxi-
mum cpm-spontaneous cpm) x 100.
Lytic units (LU) were calculated from dose-
response curves obtained by different numbers of
effector cells by using linear regression analysis, as
described previously (Uchida & Micksche, 1983b).
One LU was defined as the number of effector cells
required to induce 20% lysis of target cells, and the
results are expressed as the number of LU/106 cells.
Agarose single cell cytotoxicity assay
This assay was performed as described previously
(Uchida & Micksche, 1983a; Uchida et al., 1984).
Equal numbers (2 x 105) of nylon-wool
nonadherent lymphocytes and K562 were mixed in
0.2 ml medium, incubated for 10min at 37°C, and
centrifuged at 100g for 5 min, followed by gentle
suspension with a pipette. One per cent agarose
(0.5 ml; Sea Plaque, Marine Colloids, Rockland,
MA, USA) that had been kept in the liquid phase
at 37°C was added to the conjugate suspension.
One hundred p1 of the agarose-conjugate mixture
were transferred on to agar-precoated microscope
slides. After the solidification of agarose, the slideNK SUPPRESSION BY IFN 485
was placed in plastic dishes, filled with warm
complete medium, and incubated for 4h at 37°C.
After incubation, the slide was stained with 0.2%
trypan blue and fixed with 1% formaldehyde. The
percentage of lymphocytes forming conjugates with
K562 was determined by counting 200 lymphocytes,
and that of lytic conjugate with dead target cells
was scored by counting 100 conjugates.
Spontaneous target cell death was assessed by
counting 200 target cells in samples incubated in
the absence of effector cells and did not exceed 5%.
The percentage of active killer cells was calculated
by the formula: % Active killer cells=%
conjugate x % lytic conjugate x (1-% spontaneous
target death).
In vitro treatment with IFN or OK432
Effector cells at a concentration of 106 ml-' in
complete medium were incubated alone or with
1,000 IU IFN/ml (Heriff Medical Aps) or 50 jug
OK432/ml (Chugai Pharmaceutical Co., Tokyo,
Japan) for 12 h at 37°C in a humidified 5% CO2
atmosphere, as described previously (Uchida &
Micksche, 1981b, 1983b, 1983c). After incubation,
the cells were washed and suspended in complete
medium.
NK suppressor assay
Effector cells (106ml-') in complete medium were
precultured overnight alone or with half the number
of cells used as suppressors either in the presence or
absence of IFN (1,000 IUml- ), as described
previously (Uchida & Micksche, 1981a, 1983b).
After incubation the cells were harvested, washed
and suspended in complete medium. There were no
differences in the recovery of viable effector cells
cultured alone and with suppressor cells.
Statistical analysis
All determinations were made in triplicate, and the
results were evaluated for statistical significance by
Student's t-test.
Results
Blood NK cell activity after IFN administration
Peripheral blood lymphocytes (PBL) from cancer
patients receiving IFN injection and from normal
donors were tested for cytotoxicity against K562 in
a 4 h "Cr release assay before and 2, 4, 12, and
24 h after a single injection of 2 x 106 IU IFN.
Blood NK cell activity remained unchanged during
the first 2 h (Table I). A depression of blood NK
cell activity was observed 4h after IFN injection
and reached a nadir at 12h. Blood NK cell activity
then returned to and exceeded pretreatment levels
within 24h. In contrast, no significant changes in
blood NK cell activity was found in normal
controls during the observation period of 24 h.
These results indicate that the change in blood NK
cell activity observed in cancer patients treated with
IFN is not attributed to the diurnal variation of
blood NK cell activity nor due to time-related
variance of cytotoxicity assays but results from the
effects of injected IFN on the NK system of the
patients. Results of 12 patients are shown in Figure
1. The initial decline in blood NK cell activity at
12h points of IFN treatment was documented in
10/12 (83.3%) patients. Twenty-four hours after IFN
injection blood NK cell activity returned to base
line levels in 2 patients and exceeded pretreatment
levels in another 8 patients. Thus, these patients
were considered as responders. The other 2 patients,
however, showed no depression nor increase in
Table I Kinetics of blood NK cell activity after IFN administration
IFN-treateda Controlb
Period after IFN
injection (h) % Cytotoxicityc LU/106 % Cytotoxicity LU/106
0 32-4 41.9 42.9 83.6
2 31.5 40.0 41.4 80.0
4 24.7d 28.1d 44.6 86.9
12 6.2d 4.8 43.5 81.4
24 40.6d 74.1d 42.3 80.5
aBlood lymphocytes from a cancer patient and a normal donors were tested for
cytotoxicity against K562 in a 4h "Cr release assay before and 2, 4, 12, and 24h after
IFN injection (1 x 106 U) to the patients.
bNo IFN given.
cAt an effector to target cell ratio (E:T) of 10:1.
dValue is significantly different from that ofOh (P<0.05).486 A. UCHIDA et al.
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Figure 1 Blood NK cell activity of patients before
and 12 h and 24 h after IFN injection. Data are
expressed as % cytotoxicity against K562 at an E:T of
1O: in a 4 h 5'Cr release assay.
blood NK cell activity during 24 h post IFN
administration and thus were considered as
nonresponders.
On the other hand, there were no significant
differences in the frequencies of LGL among PBL
obtained before and 12 h and 24 h after IFN
injection [14.3+ 1.8% vs. 13.5+1.7% vs. 14.6 +1.8%
(mean +s.e.)]. While the NK cells are not
synonymous with or equivalent in number to LGL,
more than 50% LGL have been reported to
function as active NK cells against highly sensitive
target cells (Timonen et al., 1982). Taken together,
these results suggest that the initial decline or the
later increase in blood NK cell activity after IFN
administration is unlikely to be derived from a
redistribution of NK cells but may rather result
from a reduction of the lytic activity of blood NK
cells.
Analysis ofNK cell activity at single cell level
In an attempt to determine whether the initial
decline in blood NK cell activity following IFN
administration is attributable to a decrease in
frequency of lymphocytes binding to target cells or
due to a reduction of post-binding lytic function of
effector cells, nylon-wool nonadherent cells were
tested for their binding capacity and killing activity
in a 4 h single cell cytotoxicity assay in agarose
before and 12h after IFN injection. The frequency
of lymphocytes forming conjugates with K562
remained unchanged during the first 12h of IFN
treatment (Table II). There was no difference in the
Table II Reduction of NK cell activity after IFN administration
determined in single cell cytotoxicity assay in agarose
% Conjugate % Lytic conjugate % Active killer
Patient Oh 12h Oh 12h Oh 12h
1 13 11 25 8b 3.39 0.84b
2 6 6 14 gb 0.80 0.51b
3 9 7 18 llb 1.55 0.74b
4 9 10 17 12b 1.45 1.14b
5 14 13 30 29 4.07 3.94
6 16 16 26 25 3.95 3.80
7 8 8 15 lb 1.15 0.84b
8 10 9 23 job 2.19 0.86b
9 12 11 25 job 2.85 1.05
10 15 14 26 gb 3.74 1.21
11 10 10 21 12b 2.04 1.16b
12 7 5 15 7b 1.02 0.34b
aNylon-wool nonadherent lymphocytes obtained before (Oh) and 12 h
after IFN injection were tested for binding and killing activities in a 4h
single cell cytotoxicity assay in agarose.
bValue is significantly lower than that of0-h (P<0.05).
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mean percentage conjugates before and 12 h post
IFN injection (9.9+0.8% vs. 9.1+0.8%). In contrast,
the number of conjugates with dead target cells was
reduced by IFN administration. The mean
percentage of lytic conjugates observed 12 h post
IFN injection was significantly lower than that
observed before IFN injection (9.9+0.5% vs. 19.9
± 1.3%). Thus, the frequency of active NK cells
among PBL obtained 12 h post IFN injection was
estimated to be significantly lower than that before
the initiation of IFN therapy (0.87%+0.08% vs.
2.02+0.29%). The reduction of active NK cells was
recorded for all 10 responder patients. On the other
hand, nonresponder patients showed no changes in
frequencies of conjugates, lytic conjugates, and
active NK cells with IFN administration. These
results indicate that IFN administration to cancer
patients results in a rapid reduction of active NK
cells in the peripheral blood and that this could be
responsible for the initial decline in blood NK cell
activity in the IFN-treated patients.
In vitro responsiveness to NK-enhancing effect of
IFN ofIFN-treatedpatients
Since IFN has been reported to enhance the post-
binding lytic function of effector cells (Ortaldo &
Herberman, 1980; Targan & Dorey, 1980) and since
the post-binding lytic activity was found to be
impaired in PBL obtained from patients 12h after
IFN injection (Table II), PBL obtained 12h post
IFN injection were stimulated in vitro with the
same IFN preparation that had been administred to
the patients. In vitro exposure to IFN failed to
augment NK cell activity both from responders and
nonresponders (Figure 2B). Other types of IFN,
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IFN-fl or IFN-y, were also incapable of activating
PBL obtained 12 h post IFN injection (data not
shown). The unresponsiveness to in vitro IFN of
PBL from responders was induced by IFN
administration since PBL obtained before IFN
injection were activated in vitro by IFN to express
enhanced NK cell activity (Figure 2A). In contrast,
no positive reactions were recorded for PBL from
nonresponders regardless of IFN administration.
These results indicate that IFN administration to
cancer patients renders PBL unresponsive to in
vitro NK-boosting effects of IFN by 12h despite
that these PBL retain their ability to bind target
cells.
Recoveryfrom unresponsiveness to IFN ofPBL after
in vitro culture
The next set of experiments was performed to
examine whether PBL isolated from patients 12h
after IFN administration could again obtain their
responsiveness to IFN. Nylon-wool nonadherent
lymphocytes obtained at 12 h points of IFN
injection were cultured in vitro overnight in
complete medium and then stimulated with IFN for
12 h. These cultured lymphocytes showed
augmented NK cell activity in response to IFN,
whereas fresh lymphocytes showed no such
augmentation (Table III). There were no significant
differences in cytotoxicity of fresh and cultured
lymphocytes. On the other hand, nonadherent
lymphocytes from nonresponder patients were still
unresponsive to NK-enhancing effects of IFN even
after in vitro culture (data not shown). These results
indicate that PBL obtained from patients 12 h post
IFN administration recover from unresponsiveness
0 10 20 30 40 50 60 0 1Q 20 30 40 50 60
Unstimulated cytotoxicity (%)
Figure 2 In vitro effects of IFN on NK cell activity of blood lymphocytes obtained before (a) and 12 h (b)
and 24h (c) after IFN injection. Blood lymphocytes were incubated for 12 h alone or with 1,000 IU
IFNml 1, then washed and tested for cytotoxicity against K562 at an E:T of 10:1 in a 4h 51Cr release assay.
(0) responder patients who showed augmented blood NK cell activity 24h after IFN injection; (A)
responders whose blood NK cell activity returned to base line levels 24h post IFN injection; (-)
nonresponders whose blood NK cell activity was not modified by IFN injection.
7f)488 A. UCHIDA et al.
Table III Recovery from unresponsiveness to IFN
of blood lymphocytes obtained 12h post IFN
injection by in vitro culture
% Cytotoxicityb
Patient Effector cells' Medium IFNC
3 Fresh 8.9 8.3
Cultured 8.7 21.1d
4 Fresh 15.1 12.9
Cultured 15.4 29.5d
8 Fresh 11.3 11.2
Cultured 14.0 26.8d
9 Fresh 11.2 6.3
Cultured 12.5 23.7d
10 Fresh 16.7 14.7
Cultured 19.6 33.7d
aNylon-wool nonadherent lymphocytes obtained
12 h after IFN injection were used either
immediately or after overnight culture in vitro in
complete medium.
bCytotoxicity against K562 at an E:T of 10:1 in
a 4h " Cr release assay.
cFresh or cultured lymphocytes were incubated
alone or with 103 U IFNml-' for 12h, then
washed and tested.
dValue is significantly higher than that of
corresponding control cells (P<0.05).
to IFN after in vitro culture and thus contain IFN-
inducible pre-NK cells.
Suppression ofIFN-induced augmentation ofNK cell
activity by monocytes obtained 12h post IFN
administration
Adherent types of suppressor cells have been shown
to inhibit the development of functional NK cells
by IFN (Uchida & Micksche, 1983b; Uchida et al.,
1984b). To ascertain whether adherent cells
obtained 12h post IFN administration suppress
IFN-induced enhancement of NK cell activity,
nonadherent lymphocytes isolated from untreated
patients were stimulated in vitro with IFN in the
presence of blood monocytes obtained either before
or 12 h after IFN injection. In vitro exposure to
IFN caused an enhancement of NK cell activity in
the presence of monocytes from untreated patients
(Table IV). In the presence of monocytes obtained
12h post IFN injection, however, nonadherent
lymphocytes failed to express augmented NK cell
activity in response to IFN, although the base line
level of NK cell activity was not inhibited by these
monocytes. The presence of suppressor monocytes
was recorded in 9/10 (90.0%) responder patients
12 h post IFN injection. Nonadherent lymphocytes
had no such suppressive activity (data not shown).
Table IV Suppression of IFN-induced augmentation of
NK cell activity by monocytes obtained 12h post IFN
injection
% Cytotoxicity of0-h lymphocytes?
0-h monocytes added 12-h monocytes added
Patient Medium IFN Medium IFN
1 31.0 40.4b 30.5 29.1
2 9.5 37.5b 11.7 12.8
3 20.3 31.8b 19.0 18.6
4 20.0 37.1" 18.4 20.1
5 50.9 49.7 48.3 47.9
6 50.1 52.5 53.4 56.6
7 31.1 44.3 35.0 35.0
8 32.1 41.6b 27.3 42.4b
9 30.6 50.8b 30.6 33.8
10 43.0 68.2b 45.6 51.4
11 29.0 37.7b 31.2 31.1
12 17.3 28.8 15.0 18.9
aNylon-wool nonadherent cells obtained before IFN
injection (0-h lymphocytes) were incubated for 12h alone
or with IFN (103 Uml-') either in the presence or
absence of half the number of monocytes obtained before
(0-h monocytes) or 12h after (12-h monocytes) IFN
injection, then washed and tested for cytotoxicity against
K562 at an E:T of 10:1 in a 4h "Cr release assay.
'Value is significantly higher than that of controls
(P<0.05).
These results suggest that IFN administration to
cancer patients results in a rapid appearance of
suppressor monocytes capable of inhibiting IFN-
induced development of NK cell activity in the
peripheral blood and that this could be involved in
the rapid loss of reactivity to IFN of PBL observed
in the patients 12 h after IFN injection.
In vitro augmentation ofNK cell activity by OK432
Since OK432 has been demonstrated to enhance
NK cell activity in the presence of adherent
suppressor cells (Uchida & Micksche, 1983b),
attempts were next made to investigate whether NK
cell activity of PBL obtained from patients 12 h
post IFN administration is augmented by OK432
and whether OK432 enhances NK cell activity in
the presence of suppressor monocytes from IFN-
treated patients. In vitro treatment with OK432
resulted in an enhancement of NK cell activity of
nonadherent lymphocytes obtained from untreated
patients in the presence of suppressor monocytes
obtained 12 h post IFN injection (Table V).
Furthermore, PBL obtained from patients 12 h post
IFN injection were activated by OK432 to show
enhanced NK cell activity. These results indicate
that the peripheral blood of cancer patients at 12 h
points of IFN treatment contains cytotoxicNK SUPPRESSION BY IFN 489
Table V In vitro augmentation of NK cell activity by OK432
% Cytotoxicityb
Patient Effector cellsa Medium OK432
2 0-h lymphocytes 10.9 46.4c
0-h lymphocytes+ 12-h monocytes 11.7 36.1c
12-h lymphocytes 5.4 19.9c
3 0-h lymphocytes 22.4 38.6c
0-h lymphocytes+ 12-h monocytes 19.0 35.6c
12-h lymphocytes 8.9 28.5c
4 0-h lymphocytes 22.1 35.6c
0-h lymphocytes+ 12-h monocytes 18.4 34.8c
12-h lymphocytes 15.2 26.0c
11 0-h lymphocytes 30.3 60.0c
0-h lymphocytes+ 12-h monocytes 31.2 56.6c
12-h lymphocytes 16.5 52.0c
12 0-h lymphocytes 12.8 31.0c
0-h lymphocytes+ 12-h monocytes 15.0 38.5c
12-h lymphocytes 3.5 15.0c
aNylon-wool nonadherent lymphocytes obtained before IFN injection
(0-h lymphocytes), 0-h lymphocytes plus half the number of monocytes
obtained 12h post IFN injection (12-h monocytes), and nonadherent
lymphocytes obtained 12 h post IFN (12-h lymphocytes) were each
incubated for 12 h alone or with OK432 (50 gml 1), then washed and
tested for cytotoxicity.
bCytotoxicity against K562 at an E:T of 10:1 in a 4h "Cr release
assay.
cValue is significantly higher than that of controls (P<0.05).
potential, which could be activated by OK432, but
not by IFN.
Reactivity ofIFN ofPBL obtained 24h post IFN
administration andpossible role ofsuppressor
monocytes
It seemed important to test whether suppressor
monocytes were still present in the peripheral blood
of patients 24 h after IFN administration. First,
PBL obtained from patients 24 h post IFN injection
were stimulated in vitro with IFN. IFN failed to
augment NK cell activity in 8/9 (88.9%) cases where
blood NK cell activity was already enhanced in vivo
by IFN injection at 24 h (Figure 2C). An increase in
NK cell activity was recorded for one PBL sample
whose NK cell activity did not exceed base line
levels 24 h after IFN injection. PBL from two
nonresponsers were still unresponsive to IFN. Next,
PBL from normal donors were incubated alone or
with IFN either in the presence or absence of blood
monocytes obtained from patients 24 h after IFN
administration. In vitro treatment with IFN resulted
in an augmentation of NK cell activity of control
lymphocytes regardless of the presence of
monocytes (Table VI). These blood monocytes also
Table VI Effects of monocytes obtained 24h post IFN
injection on NK cell activity
% Cytotoxicityb
24-h monocytes
Experiment addeda Medium IFN
2 None 33.0 46.0c
Added 32.1 44.5C
3 None 26.4 44.3c
Added 30.5 43.9c
7 None 41.2 58.1c
Added 40.3 57.8c
9 None 20.7 31.4c
Added 23.5 34.6c
10 None 38.8 59.8c
Added 36.5 60.2c
aNylon-wool nonadherent cells from normal donors
were incubated for 12h alone or with IFN (1,000 Uml-')
either in the presence or absence of half the number of
monocytes from cancer patients (Nos. 2, 3, 7, 9, 10)
obtained 24h after IFN injection, then washed and tested.
bCytotoxicity against K562 at an E:T of 10:1 in a 4h
5'Cr release assay.
cValue is significantly higher than that of controls
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had no suppressive activity to autologous blood
lymphocytes obtained before IFN injection (data
not shown). These results suggest that PBL
obtained 24 h after IFN administration are
activated in vivo by IFN to a great extent and
therefore cannot respond in vitro to IFN and that
blood monocytes are not involved in the
unresponsiveness of these lymphocytes to NK-
enhancing effects of IFN.
Discussion
In the present report, several observations have
been made concerning the effects of IFN on
cytotoxic activity of NK cells and NK regulatory
function of monocytes. A single i.m. injection of
IFN-a to cancer patients has resulted in an initial
decline in blood NK cell activity, being detectable
at 4h, reaching a nadir at 12 h and returning to or
exceeding pretreatment levels within 24 h. Similar
initial depression of blood NK cell activity after
IFN administration has been documented in
patients with chronic hepatitis at 4h (Pape et al.,
1981), in normal donors at 6h (Karimiemi et al.,
1980), and in cancer patients at 12h (Koren et al.,
1983) or at 24h (Golub et al., 1982a, 1982b).
There are several possible explanations for the
initial depression of blood NK cell activity caused
by IFN administration; generation of suppressor
elements, redistribution of NK cells, intrinsic defects
in NK cells, and impaired development of active
NK cells from pre-NK cells. Data presented in this
report indicate that adherent blood cells obtained
from patients 12 h after IFN injection are not
suppressive to NK cells even after overnight
contact. Nonadherent lymphocytes from IFN-
treated patients also had no suppressor function
(data not shown). Our findings are in keeping with
previous reports that adherent suppressor cells are
not involved in the initial decline in blood NK cell
activity after IFN administration (Golub et al.,
1982b). In contrast, other investigators have
reported that 2/3 patients develop nonadherent
suppressor cells 12 h post IFN injection (Koren et
al., 1983). The reason for this discrepancy is not
understood. It may be due to the differing
responsiveness of patients' lymphocytes to IFN
since the initial depression of blood KN cell activity
after IFN administration is more profound in their
patients than in ours.
It has been demonstrated that both pre-NK cells
and active NK cells have the ability to recognize
NK-susceptible target cells and that pre-NK cells
lack the capacity to kill these target cells (Ortaldo
& Herberman, 1980; Targan & Dorey, 1980;
Reynold et al., 1982). The single cell level assay in
the present study has revealed that the frequency of
lymphocytes forming conjugates with K562 target
cells is not reduced at the time when blood NK cell
activity is depressed in a population level assay.
This may indicate that the total number of pre-NK
cells and active NK cells is not affected by IFN
administration. The single cell level assay has
further demonstrated that the frequency of active
NK cells is decreased along with the initial decline
in blood NK cell activity determined in a 5"Cr
release assay. In addition, the number of LGL
among PBL has remained unchanged during the
first 12 h of IFN treatment. Collective data suggest
that the in vivo IFN-induced initial decline in blood
NK cell activity is unlikely to be due to
redistribution of NK cells following IFN
administration but may rather result from
suppression of functional development of active NK
cells from pre-NK cells. Similar studies in another
group have implied no change in the binding
capacity of NK cells at the time of the initial
depression of blood NK cell activity caused by IFN
injection (Golub et al., 1982b).
We have previously demonstrated that adherent
cells from carcinomatous pleural effusions of cancer
patients and from the peripheral blood of
postoperative cancer patients suppress the
maintenance of functional NK cells and
development of active NK cells in response to IFN
(Uchida & Micksche, 1981a, 1983b; Uchida et al.,
1982, 1984a). In the present study blood monocytes
obtained from patients 12h after IFN
administration suppressed IFN-induced
augmentation of NK cell activity, although these
suppressor cells did not inhibit the maintenance of
functional NK cells. The same type of adherent
suppressor cells has quite recently been documented
in bone marrow of normal individuals (Uchida et
al., 1984b). On the other hand, it has been proposed
that both pre-NK cells and active NK cells are
present in the peripheral blood and that
endogenous IFN stimulates pre-NK cells to become
active NK cells (Ortaldo & Herberman, 1980;
Targan & Dorey, 1980; Reynold et al., 1982). Taken
together, it seems likely that the development of
active NK cells from pre-NK cells is suppressed by
blood monocytes in cancer patients shortly after
IFN administration and that this could be
responsible for the decline in blood NK cell activity
in the patients observed 12h post IFN injection.
Indeed, blood NK cell activity is found to return to
or exceed base line levels within 24h of IFN
therapy, and monocytes obtained at 24h points of
IFN treatment are no longer able to inhibit IFN-
induced enhancement of NK cell activity. This
suggests that blood monocytes rapidly lose their
suppressive activity to NK cells in vivo. This
suggestion was confirmed by in vitro data which
showed that suppressor monocytes obtained 12 hNK SUPPRESSION BY IFN 491
post IFN injection lose their inhibitory capacity for
IFN-dependent development of active NK cells
after overnight culture in vivo (data not shown).
Previous reports have indicated that PBL
obtained 12 h after IFN administration not only
express depressed NK cell activity but also lack
responsiveness to NK-boosting effects of IFN in
vitro (Koren et al., 1983). These authors argue that
the initial decline in blood NK cell activity after
IFN injection is in part due to a loss of specific cell
type associated with NK cell activity. Similarly,
PBL obtained 12 h post IFN injection failed to
respond in vitro to IFN in the present study.
However, the frequency of LGL among PBL and
the number of lymphocytes forming conjugates with
target cells were not reduced by IFN injection.
Furthermore, PBL at 12h points of IFN therapy
recovered their responsiveness to NK-boosting
effects of IFN after in vitro culture. In addition,
PBL from IFN-treated patients were activated by
OK432 to express increased NK cell activity.
OK432 has been reported to enhance NK cell
activity of LGL with pre-existing ability to
recognize target cells (Uchida & Micksche, 1981b).
Collectively, it seems likely that the initial
depression of blood NK cell activity after IFN
administration is unlikely to be due to a loss of NK
cells in the blood but rather attributable to the
unresponsiveness to IFN of pre-NK cells.
In conclusion, a significant but transient decline
in blood NK cell activity has constantly been
observed in cancer patients 12 h after IFN
administration. The initial reduction of blood NK
cell activity has been detected even after repeated
injections of IFN (data not shown). The generation
of suppressor monocytes capable of inhibiting IFN-
dependent development of functional NK cells
appears to be involved in the initial depression of
blood NK cell activity, although the mechanism by
which suppressor monocytes appear in the
peripheral blood shortly after IFN injection remains
unclear. It could be postulated that a transition of
pre-NK cells to active NK cells is regulated by
monocytes.
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